Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies targeting highly resistant cancers and emerging viral pathogens. The company’s scientific approach centers on leveraging small-molecule inhibitors to disrupt critical pathways in tumor cells and viral replication, with the goal of delivering therapies that can overcome resistance mechanisms and improve patient outcomes.
The company’s oncology pipeline features lead candidates such as Annamycin, an anthracycline derivative designed to evade multidrug resistance pumps in tumor cells, and WP1066, an immune-modulating agent that inhibits the STAT3 signaling pathway implicated in various solid tumors and hematologic malignancies. In parallel, Moleculin Biotech is advancing its antiviral program, highlighted by WP1122, a prodrug engineered to suppress viral replication by targeting glycolytic enzymes, which has potential applications against coronaviruses and other RNA viruses.
Since its inception in 2017 and headquarters in Houston, Texas, Moleculin Biotech has built a multidisciplinary team combining expertise in medicinal chemistry, oncology, virology, and clinical development. Under the leadership of Chairman and Chief Executive Officer Dr. Walter Klemp and Chief Scientific Officer Dr. Mikhail Kireev, the company has initiated multiple Phase 1 and 2 clinical trials across its pipeline, collaborating with major cancer centers and research institutions to evaluate safety, pharmacokinetics, and early signs of efficacy.
Moleculin Biotech’s clinical studies are conducted in the United States and select international sites, reflecting the company’s commitment to global access and regulatory engagement. By pursuing both oncology and infectious disease indications, the company aims to address urgent unmet medical needs and establish strategic partnerships that can accelerate development and broaden patient reach. Through this integrated model, Moleculin Biotech continues to advance its novel drug candidates toward commercialization and broader clinical adoption.
AI Generated. May Contain Errors.
